Why pharma should invest in evidence-based physician education
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. Today’s molecular-targeted therapies have very different treatment paradigms, not to mention cost structures.